Document:

EX-10.64

CONFIDENTIAL

280 East Grand Avenue

South San Francisco, CA 94080

Tel (650) 624-3000 Fax (650) 624-3010

June 18, 2007

	 	 	 	 	 
	GlaxoSmithKline
2301 Renaissance Boulevard
Building #510
RN0420
King of Prussia, Pennsylvania
	 	 	19406	 
	Attn:
	 	Scott Klesmer

Director, Alliance Management

Re: Second Extension of the Research Term with respect to CENP-E under that certain Collaboration
and License Agreement by and between Glaxo Group Limited, a GlaxoSmithKline company,
(“GSK”) and Cytokinetics, Inc. (“CK”), dated June 20, 2001, as amended (the
“Collaboration Agreement”)

Dear Scott:

Pursuant to this letter amendment to the Collaboration Agreement (the “Letter Amendment”),
GSK and CK desire to further extend the Research Term solely with respect to that certain Mitotic
Kinesin Target known as CENP-E, all on the terms set forth herein.

Now therefore, GSK and CK agree, effective as of June 19, 2007, as follows:

	 	1.	 	All capitalized terms not defined herein shall have the meaning ascribed to them in
the Collaboration Agreement.

	 	2.	 	Notwithstanding GSK’s obligation to notify CK in writing of its exercise of its
option to extend the Research Term under Section 2.8.1 of the Collaboration Agreement, the
Research Term is hereby extended for an additional one-year period to expire on June 19,
2008 solely with respect to CENP-E to allow for the conduct of Research Program activities
directed to CENP-E. In addition, the first two occurrences of “June 19, 2007” in Section
5(a) of the “Amendment to Collaboration and License Agreement” between CK and GSK, dated
November 27, 2006 (the “November 2006 Amendment”) are hereby changed to “June 19,
2008.”

	 	3.	 	For clarity, in light of the present extension, GSK may only extend its rights under
Section 4.2.3 of the Collaboration Agreement and only with respect to CENP-E for a further
[***]-year Extension Period under Section 4.2.2 of the Collaboration Agreement, as
contemplated in Section 4.2.2(d) of the Collaboration Agreement and subject to the
November 2006 Amendment, unless otherwise agreed by the Parties.

*** Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

1

CONFIDENTIAL

	 	4.	 	Except for the amendment of Section 5(a) of the November 2006 Amendment in the manner
described in paragraph 2 above, the November 2006 Amendment is unaffected by this Letter
Amendment.

	 	5.	 	The Research Plan for the extended Research Term is attached as Exhibit A hereto.

	 	6.	 	The Parties hereby agree that the number of JRC representatives shall be four (4) for
each of GSK and CK. All other terms and conditions of Section 2.2(a) remain unchanged.
GSK hereby notifies CK that its JRC representatives shall be those individuals identified
in Exhibit B hereto; and CK hereby notifies GSK that its JRC representatives shall be
those individuals identified in Exhibit B hereto.

	 	7.	 	Notwithstanding Section 2.8.1 of the Collaboration Agreement, GSK has no obligation
to fund any CK FTEs during this extension of the Research Term for CENP-E.

	 	8.	 	Each Party agrees to execute, acknowledge and deliver such further instruments, and
to do all such other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Letter Amendment.

	 	9.	 	Except as specifically modified or amended hereby, the Collaboration Agreement shall
remain in full force and effect and, as modified or amended, is hereby ratified, confirmed
and approved. No provision of this Letter Amendment may be modified or amended except
expressly in a writing signed by both Parties, nor shall any terms be waived except
expressly in a writing signed by the Party charged therewith. This Letter Amendment shall
be governed in accordance with the laws of the State of New York, without regard to
principles of conflicts of laws.

Please sign and return two copies of this Letter Amendment if you agree to the foregoing terms.

Sincerely,

/s/ Robert I. Blum

Robert I. Blum

President and Chief Executive Officer

Cytokinetics, Inc.

Agreed and accepted:

GLAXO GROUP LIMITED

/s/ Paul Blackburn

Name: Paul Blackburn

Title: Director 

Page 2 of 5

2

CONFIDENTIAL

	 	 	 
	cc:

	 	SVP WW Business Development, GlaxoSmithKline

Lisa A. DeMarco, Esq., Vice President & Associate General

Counsel, GlaxoSmithKline, R&D Legal Operations

Kenneth A. Clark, Esq., Wilson Sonsini Goodrich & Rosati Professional Corporation

Page 3 of 5

3

CONFIDENTIAL

Exhibit A

Research Plan *

[***]

Page 4 of 5

*** Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

4

CONFIDENTIAL

Exhibit B

JRC Members

[***]

Page 5 o5

*** Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

5EX-10.1

RESIGNATION AND SEVERANCE AGREEMENT

This Resignation and Severance Agreement (this “Agreement”) is entered into as of
June 18, 2007, between SCM Microsystems GmbH (“SCM GmbH”), SCM Microsystems, Inc. (“SCM
Inc.” and, together with SCM GmbH and each of their respective subsidiaries, the
“Company”) and Robert Schneider (“Employee”).

The purpose of this Agreement is to arrange for Employee’s resignation from any and all
positions that he holds or may be deemed to hold with or in the Company, including, without
limitation, as (i) the Chief Executive Officer of SCM Inc., (ii) the Managing Director of SCM GmbH
and (iii) a member of the Board of Directors of SCM Inc. (and, to the extent applicable, each of
its subsidiaries, collectively, the “Board”), and to terminate all existing employments and
to set forth the terms of the Employee’s release of claims and severance package, all on a basis
that is satisfactory both to Company and to Employee (together, the “Parties”). In
consideration of the promises and obligations set forth herein, SCM GmbH agrees to provide certain
additional benefits to Employee in full satisfaction of its obligations under the employment
relationship between the Parties, and Employee agrees to release the Company from any claims or
obligations as set forth herein.

1. Resignation. Subject to Section 7(b) below, by signature under this
Agreement, the Employee irrevocably resigns from (i) his positions as Chief Executive Officer of
SCM Inc. and Managing Director of SCM GmbH, (ii) his position as a member of the Board and
(iii) any and all other positions that he holds or may be deemed to hold with or in the Company, in
each case, effective as of June 30, 2007 (the “Termination Date”). Employee shall on the
date hereof execute the resignation letter attached as Exhibit A hereto, which letter,
subject to Section 7(b) below, will be submitted by SCM GmbH to the appropriate court
and/or governing authority for deregistration upon the expiration of the Revocation Period (as
defined in Section 7(b) below), and Employee hereby consents to the submission of such
letter to any such court and/or governing authority. Subject to Sections 2, 7(b) and
8(a) below, on the Termination Date, Employee’s employment with the Company and its
affiliates and any employment agreement between Employee, on the one hand, and the Company or any
of its affiliates, on the other hand, including, without limitation, the Employment Contract dated
August 26, 1993, as amended by the Agreement dated May 22, 2006 (together, the “Employment
Agreements”), will terminate. Employee understands and agrees that this termination is
effective with respect to any and all positions he holds with the Company and any of its
affiliates.

2. Restrictive Covenant. Notwithstanding Section 1, the Restrictive Covenant
between Kudelski S.A. and Employee dated as of April 5, 2006 (the “Restrictive Covenant”)
shall remain in full force and effect.

3. Accrued Benefits; Benefit Plans. On or before the Termination Date, SCM GmbH will
pay Employee all wages due to him, including regular base salary, through the Termination Date.
Parties agree that all vacation entitlement from and for past years and for the year 2007 until
Termination Date has been fully granted and used. . In addition, SCM GmbH will reimburse Employee
in a timely fashion for all approved business expenses incurred by Employee prior to the
Termination Date in accordance with normal SCM GmbH policy. Employee acknowledges and agrees that
following the Termination Date, Employee shall no longer be an active participant in any of the
Company’s employee benefit, incentive or bonus plans, programs, policies or arrangements
(collectively, “Benefit Plans”), and shall have only those rights under the Benefit Plans
provided to former employees in accordance with the express terms of such Benefit Plans.

4. Compensation Package. Notwithstanding anything to the contrary contained in the
Employment Agreements, SCM GmbH agrees that following the Termination Date and upon expiration of
the Revocation Period (as defined in Section 7(b) below) and subject to Employee’s
continued compliance with the Restrictive Covenant and the NDA and Non-Compete Covenants (as
defined below), Employee shall be eligible to receive the following:

(a) Compensation Payments. Payments equal to Employee’s monthly gross base salary,
EURO 29,166.67, for a period of thirty (30) months after the Termination Date (“Compensation
Period”), to be paid at the rate in effect on the Termination Date in accordance with SCM
GmbH’s standard payroll procedures and after deduction of wage tax and social security
contributions, if any. As far as Employee is entitled to the payments set forth under this
Section 4 for a period during which the NDA and Non-Compete Covenants apply, the
compensation payments shall be understood as compensation for the post-contractual non-compete
covenants contained in the Restrictive Covenant and the NDA and Non-Compete Covenants. If and as
far as the payments set forth under this Section 4 fall in a period after the end of the
period during which the NDA and Non-Compete Covenants apply, any such payments shall be understood
as severance payments.

(b) Bonus Payment. Employee will receive any earned and unpaid bonuses under the
terms of his Employment Agreements, less customary withholdings, within 60 days following the
Termination Date. With respect to a bonus, if any, for the period of fiscal 2007 prior to the
Termination Date, the amount of such bonus, if any, shall be determined in the sole discretion of
the Board or the Compensation Committee thereof, as the case may be, and shall be paid in
accordance with SCM GmbH’s bonus plan. No bonus is owed for the time after Termination Date.

5. Equity Benefits. Exhibit B to this Agreement sets forth Employee’s rights
to purchase shares of SCM Inc.’s capital stock as of the Termination Date (assuming that Employee
continues to be employed by the Company through the Termination Date). Employee acknowledges and
agrees that Employee’s rights with respect to the shares (or the purchase thereof) described on
Exhibit B shall be governed solely by the stock option agreements and plans under which
such shares or rights to purchase were granted. Employee further acknowledges and agrees that,
except as set forth on Exhibit B and in those stock option agreements and plans that govern
Employee’s rights with respect to the shares (or the purchase thereof) described on
Exhibit B, Employee has no other right, title, interest, or claim in or to any shares of
the Company’s capital stock, other than any shares of SCM Inc. that he might own that are
unencumbered by any contractual restrictions in favor of the Company. For the avoidance of any
doubt, the parties acknowledge and agree that, in accordance with the notice provisions set forth
in the Employment Agreement, any stock option, restricted stock or other equity inventive award
granted to Employee under the Company’s stock option plans that is outstanding on the Termination
Date (a) shall continue to vest, in accordance with its respective vesting schedule, until December
31, 2007, and (b) shall continue to be exercisable until March 31, 2008, at which time it shall
expire and be canceled and no longer be in force or effect, in each of (a) and (b), unless and
except to the extent otherwise provided in the stock option agreements or plans that govern
Employee’s rights with respect to such stock option, restricted stock or other equity inventive
award.

6. No Other Payments Due. Employee acknowledges and agrees that, upon payment of the
amounts set forth in Sections 3 and 4 of this Agreement, he will have received all salary,
accrued vacation, bonuses, wages, compensation or other such sums due to him.

7. Release.

(a) General Release. In consideration of the benefits to be provided to Employee by
the Company as set forth in this Agreement, Employee hereby fully and forever releases and
discharges (this “Release”) the Company, and its current and former officers, directors,
shareholders, partners, members, investors, administrators, employees, contractors, agents,
attorneys, insurers, affiliates, successors, predecessors, subsidiaries, assigns and fiduciaries,
in their individual and/or representative capacities, (collectively, the “Released
Parties”) from any and all claims, suits, agreements, promises, damages, demands, disputes,
controversies, contentions, differences, judgments, debts, dues, accounts, reckonings, bonds,
causes of action, costs, expenses, bills, attorney’s fees, covenants, contracts, executions and
demands of any kind whatsoever, which Employee ever had, now has or may have against the Released
Parties or any of them, for, upon, or by reason of, any matter, action, omission, course or thing
whatsoever occurring or arising on or before or up to the Termination Date, including, without
limitation, in connection with or in relationship to Employee’s employment or other service
relationship with the Company or its affiliates, Employee’s resignation from any and all positions
that he holds or may be deemed to hold with or in the Company, the termination of any such
employment or service relationship and any applicable employment, compensatory or equity
arrangement with the Company or its respective affiliates (such released claims are collectively
referred to herein as the “Released Claims”); provided that such Released Claims
shall not include any claims to enforce Employee’s rights under, or with respect to, this
Agreement. Employee understands and agrees that this Release is a full and complete waiver of all
claims, aside from claims pursuant to Section 4 of this Agreement, whether known or unknown
by him, suspected or unsuspected, disclosed or undisclosed, including, but not limited to, any
claims with respect to his entitlement to any wages, bonuses, vacation pay, expense reimbursements,
severance benefits or other forms of compensation; any claims with respect to his purchase of, or
right to purchase, any capital stock of the Company; any claims of wrongful discharge, breach of
contract, breach of the covenant of good faith and fair dealing, violation of public policy,
defamation, personal injury, emotional distress; any claims under Title VII of the Civil Rights Act
of 1964, as amended, the Fair Labor Standards Act, the California Fair Employment and Housing Act,
the Equal Pay Act of 1963, the Americans With Disabilities Act, California Labor Code Section
1197.5, the Civil Rights Act of 1991, the Employee Retirement Income Security Act of 1974, as
amended (“ERISA”), as related to severance benefits, any family and medical leave acts; and
any claims under any other U.S. federal, state, or local, or any non-U.S., laws and regulations
relating to employment or employment discrimination. Employee agrees that the benefits provided to
him pursuant to this Agreement are in full satisfaction and settlement of any such Released Claims.
Employee represents and warrants that he has not filed, and he will not file, any lawsuit or
institute any proceeding, charge, complaint or action asserting any such claim before any U.S.
federal, state, or local, or any non-U.S., administrative agency or court against any Released
Party, concerning any event occurring prior to the Termination Date. Nothing in this Agreement,
however, shall be construed as prohibiting Employee from filing a charge or complaint with the
Equal Employment Opportunity Commission (“EEOC”) or participating in an investigation or
proceeding conducted by the EEOC. Employee also hereby agrees that nothing contained in this
Release shall constitute or be treated as an admission of liability or wrongdoing by any of the
Released Parties.

(b) ADEA. Employee represents that he is knowingly and voluntarily waiving any and
all rights that he currently may have arising under the Age Discrimination in Employment Act of
1967, as amended. Employee understands that he has the right to consult with an attorney before
signing this Agreement. Employee also understands that he may have twenty-one (21) days after his
receipt of this Agreement within which he may review and consider, discuss with an attorney of his
own choosing, and decide to execute or not execute it. Employee further understands that for a
period of seven (7) days after he signs this Agreement, he may revoke the Release (the
“Revocation Period”). In order to revoke the Release, Employee must deliver to the
Chairman of the Board, by no later than seven (7) days after he executes this Agreement, a letter
stating that he is revoking it. Employee understands and agrees that if he revokes the Release, he
will have no right to receive, and the Company will have no obligation to make or provide, any of
the payments described in Section 4 above or any other benefits set forth in this
Agreement. If Employee does not deliver such a letter, then this Agreement shall become effective
upon the expiration of the Revocation Period, which is the seventh (7th) day after he
executes this Agreement. If Employee executes this Agreement prior to the twenty-first (21) day
after its delivery to him, Employee hereby acknowledges that his decision to execute this Agreement
prior to the expiration of such twenty-one (21) day period was entirely voluntary. Notwithstanding
anything to the contrary contained in this Agreement, the Company reserves the right to recall
Employee from any office which the Employee holds, including but not limited to the office of
Managing Director of SCM GmbH, and terminate any employment which the Employee may have, including
but not limited to the employment with SCM GmbH (based inter alia on the agreement of 1993) should
employee elect to revoke his consent to this Agreement within the seven (7) day revocation period.

(c) Full Disclosure To Company. Employee represents and hereby reaffirms that he has
disclosed to the Company any information in Employee’s possession concerning any conduct involving
the Company that Employee has any reason to believe may be unlawful or may violate Company policies
in any material respect. In addition, Employee hereby agrees that he will cooperate fully with the
Company in connection with any and all existing or future investigations or proceedings, if any,
initiated by or against the Company or any of the Released Parties, in which (and to the extent)
the Company deems Employee’s cooperation reasonably necessary. Nothing set forth in the Release
shall prevent Employee from communicating with or participating in any government investigation.
Employee will act in good faith to furnish the information and cooperation required by this
Section 7(c).

(d) No Future Employment. Employee agrees that he will not be eligible for or
entitled to re-employment with the Company or any Company-affiliated or related entities, at any
time in the future, nor will Employee file any charge, claim or lawsuit of any kind against the
Company, any Company-affiliated or related entities or the Released Parties, arising out of or in
any way related to any failure or refusal to employ Employee.

(e) Company Release. The Company hereby fully and forever releases and discharges
Employee from any and all claims, suits, agreements, promises, damages, demands, disputes,
controversies, contentions, differences, judgments, debts, dues, sums of money, accounts,
reckonings, bonds, causes of action, costs, expenses, bills, attorney’s fees, covenants, contracts,
variances, trespasses, extents, executions and demands of any kind whatsoever, which the Company
ever had, now has or may have against Employee for, upon, or by reason of, any matter, action,
omission, course or thing whatsoever occurring or arising on or before or up to the Termination
Date, including, without limitation, in connection with or in relationship to Employee’s employment
or other service relationship with the Company or its affiliates; provided that such
released claims shall not include any claims to enforce the Company’s rights under, or with respect
to, this Agreement or relating to or arising out of fraud, willful misconduct or illegal action on
the part of Employee. The Company understands and agrees that this release is a full and complete
waiver of all claims, whether known or unknown, suspected or unsuspected, disclosed or undisclosed.

8. Confidentiality and Non-Compete Covenants. The obligations of Employee
under the each of the subsections of this Section 8 are referred to collectively as the
“NDA and Non-Compete Covenants.”

(a) Confidential and Proprietary Information. Employee represents and warrants that,
at all times prior to the date on which he executes this Agreement, he has been in full compliance
with his obligation to maintain the confidentiality of all confidential and proprietary information
of the Company, including, without limitation, under the terms of the Employment Agreements.
During the Compensation Period, Employee shall strictly keep secret any confidential information
concerning the business of the Company, including, but not limited to, products, contractual
arrangements, deals, customers, prices, business strategies, raw material blending, manufacturing
processes and prospects and any other confidential affairs or information of the Company, and will
not utilize any such information in any manner for his own or for the benefit of others. After the
Compensation Period, the Employee’s duty of confidentiality as set forth in preceding sentence
shall survive. In case of a professional or entrepreneurial activity of the Employee after the
Compensation Period, he can make use of his professional knowledge acquired during the Period,
provided that, the statutory limitations, including, but not limited to, those set forth in
sections 3, 17 UWG, 823, 826 Civil Code and the Data Protection Act, or limitations arising from a
post-termination non-compete (set forth in this Agreement or otherwise), if any, are strictly
observed. Employee acknowledges that he is aware that the United States securities laws prohibit
any person who is in the possession of material non-public information about a company from
purchasing or selling that company’s securities in reliance upon such information or from
communicating such information to any other person or entity under circumstances in which it is
reasonably foreseeable that such person or entity is likely to purchase or sell such securities in
reliance upon such information.

(b) Return of Company Property. As a condition to the performance of the Company’s
obligations under this Agreement, Employee is required to return, and Employee hereby represents
that as of the Termination Date he has returned to the Company, all of the Company’s property,
documents, records and other materials, including, but not limited to, any confidential or
proprietary information, in his possession, custody or control (and all copies, whether in paper,
electronic or other format, thereof), on or before the Termination Date, except for any property
that the Company expressly agrees Employee may retain.

(c) Non-Disparagement. Employee agrees to refrain from making any derogatory,
disparaging and/or detrimental statements to any other person or third parties about the Company or
any of the Released Parties, including, but not limited to, the Company’s directors, officers,
investors, employees, products or services. Employee also agrees that he will not act in any
manner that might interfere with the business or disparage the reputation of the Company or any of
the Released Parties. The Company agrees to direct each of the current members of its Board and
its current executive officers to refrain from making any derogatory, disparaging and/or
detrimental statements to any other person or third parties about Employee. Nothing set forth in
this Section 8(c) shall prohibit or limit in any way a Party’s right to accurately and
honestly respond as required or to cooperate with any valid government, court or regulatory order
or request.

(d) Competition Prohibition. During the first twenty (20) months of the Compensation
Period, Employee agrees that he will not engage, directly or indirectly, professionally or
occasionally, for his own account or the account of a third party, independently or dependently, in
any other employment, occupation, consulting or other business activity competitive with or related
to the current or future business of the Company, nor shall Employee acquire, obtain an equity
interest in (excluding Employee’s investment in Spyrus existing as of the date of the signature of
this Agreement and in any other company of which Employee currently or in the future, beneficially
or of records owns, holds or controls, directly or indirectly, less than 5% of the equity or other
securities, in each case, solely as a passive investment), or otherwise support, an enterprise
which engages in business activity competitive with or related to the current or future business of
the Company. The restriction on competition set forth in the preceding paragraph shall especially
apply to the territory of Europe, the United States of America and Japan. As compensation for
compliance with this restriction on competition, Employee shall receive the payments set forth in
Section 4, which shall be payable as indicated therein.

(e) Inventions, Copyrights. Rights to inventions or technical improvements which
Employee made or worked out during his activity on behalf of the Company, in connection with his
activity on behalf of the Company, as a result of his experiences arising from his activity on
behalf of the Company or on the basis of studies of the Company, in each case, shall be held solely
by the Company, and, insofar as such rights have not yet been transferred to Company, Employee
hereby assigns all such rights including all applicant’s rights, the entitlement to the priority of
the rights and the right to file for intellectual property protection abroad at this time to SCM
GmbH. In particular, Employee hereby assigns and transfers to SCM GmbH all intellectual property
rights belonging to the following patent families, including, without limitation, all applicant’s
rights, the entitlement to the priority of the rights and the right to file for intellectual
property protection abroad and SCM GmbH hereby accepts the assignment and transfer of such rights:

(i) internal SCM patent number 4466 xx — Cash Mouse Patent (Mechanical Patent rel. to Class 3
reader), including the subseries S 4466 DE, S 4466 DE E, S 4466 FR, and

(ii) internal SCM patent number 4245 xx — PC Card reader Close (PCMCIA Mechanical Patent),
including the subseries S 4245 DE G, S 4245 DE E, S 4245 FR, S 4245 GB, S 4245 IT, S 4245 JP, S
4245 SE, S 4245 SG, S 4245 US.

The Company shall not be obligated to pay any additional compensation to Employee for the transfer
of any rights under this Section 8 (e). The Employee Invention Act shall not be applicable
in the absence of employee status on the part of Employee. Accordingly, Employee hereby assigns to
SCM GmbH the exclusive use, at no charge, of any copyrights arising through him for works created
in connection with his activity, as a result of his experience arising from his activities on
behalf of the Company or on the basis of studies by the Company.

9. Taxes. Any payments or benefits provided pursuant to this Agreement will be
subject to applicable tax withholdings. Employee expressly permits the Company to deduct from any
amounts due hereunder such amounts as necessary to satisfy any withholding or employment tax
obligations arising in connection with the termination of his employment, including, but not
limited to, the cancellation of any debt, the payment of any amount or the provision of any benefit
hereunder.

10. Entire Agreement. This Agreement (including the exhibits hereto) sets forth the
entire agreement between the Company and Employee and supersedes any prior agreements (including,
without limitation, the Employment Agreements) or understanding, whether oral or written,
concerning the subject matter set forth herein. This Agreement may not be altered or amended
except by a written document signed by the Parties. Employee expressly agrees that, except as set
forth herein, the terms of this Agreement supersede the terms of any individual agreement or
understanding with the Company relating to Employee’s rights as an employee of the Company,
including, but not limited to, the Employment Agreements. Employee acknowledges that he is
executing this Agreement voluntarily and knowingly and that he has not relied upon any
representation or statement made by the Company, the Released Parties or their respective agents
with respect to the subject matter, basis or effect of this Agreement, other than those
specifically stated in this Agreement. This Agreement shall be binding upon Employee and
Employee’s successors, heirs, administrators and executors and shall inure to the benefit of the
Company, the Released Parties and their respective successors and assigns. This Agreement is
drafted in both German and English version. In case of discrepancies or contradictions between the
German and the English version, the English version shall prevail.

11. Severability. Whenever possible, each provision or portion of any provision of
this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any one or more of the provisions or portions of any provisions of this Agreement shall
be or become invalid, illegal or unenforceable in any respect or to any degree, the validity,
legality and enforceability of any remaining provision of this Agreement that is not closely
related to the invalid, illegal or unenforceable provision shall not be affected thereby and said
illegal, unenforceable or invalid provisions, solely to the extent of such invalidity, illegality
and unenforceability, shall be deemed not to be a part of this Agreement.

12. Governing Law; Venue.

(a) This Agreement shall be governed, interpreted and enforced by and under the laws of the
Federal Republic of Germany, without regard to its conflicts of law provisions.

(b) The parties irrevocably consent and submit to the exclusive jurisdiction of the courts
located in Munich, Germany, for the adjudication of any dispute, suit or proceeding based on or
arising under this Agreement or in connection with any of the transactions contemplated hereby, and
irrevocably agree that all claims in respect of such suit or proceeding may be determined in such
courts. The parties irrevocably waive the defense of an inconvenient forum to the maintenance of
such suit or proceeding.

(c) To the extent permissible under procedural law, the parties further agree that service of
process upon the other party mailed by first class mail shall be deemed in every respect effective
service of process upon such party in any such suit or proceeding. Nothing herein shall affect the
right of the parties to serve process in any other manner permitted by law. The parties agree that
a final non-appealable judgment in any such suit or proceeding shall be conclusive and may be
enforced in other jurisdictions by suit on such judgment or in any other lawful manner.

13. Counterparts. This Agreement may be executed in counterparts, each of which shall
be deemed to be an original and together shall be deemed to be one and the same document.

14. Voluntary Execution. Employee hereby understands and agrees that:

(a) He has been given twenty-one (21) days from the date that this Agreement was delivered to
him (i.e., until June 18, 2007) in which to accept its terms, although he may accept it at any time
within those twenty-one (21) days;

(b) He has carefully read and fully understands all of the terms of this Agreement;

(c) He is, through this Agreement, releasing the Released Parties from any and all claims he
may have against them;

(d) He was advised and is hereby advised in writing to consult with an attorney of his choice
prior to executing this Agreement;

(e) He has so consulted with an attorney of his choice or knowingly declined to do so;

(f) He knowingly and voluntarily agrees to all of the terms set forth in this Agreement with
full appreciation that he is forever foreclosed from pursuing any of the rights waived herein;

(g) He has a period of seven (7) days after signing this Agreement within which to revoke his
consent to this Agreement and the Release and that neither the Company nor any other person is
obligated to provide any payment or benefit to him until the later of (i) at least eight (8) days
have passed since his signing of this Agreement without his signature having been revoked in a
writing received by the Company within the seven (7) day Revocation Period and (ii) the Termination
Date; and

(h) He is under no disability or impairment that affects his decision to sign this Agreement
and knowingly and voluntarily intends to be legally bound by this Agreement.

15. Non-Admission of Wrongdoing. This Agreement does not in any way constitute, and
should not be interpreted or construed, as an admission by the Company or any of the Released
Parties or any of their respective agents of any wrongdoing or inappropriate conduct with respect
to Employee or any other person, or that Employee has any rights whatsoever against the Company,
any of the Released Parties or any of their respective agents. The Company specifically disclaims
any liability or wrongful acts against Employee or any other person on the part of the Company or
any of the Released Parties.

1

[Signature Page Follows]

PLEASE READ CAREFULLY. THIS RESIGNATION AND SEVERANCE AGREEMENT INCLUDES A RELEASE OF

ALL KNOWN OR UNKNOWN CLAIMS. THE PARTIES HAVE READ THIS AGREEMENT, HAVE HAD THE OPPORTUNITY TO

CONSULT WITH COUNSEL PRIOR TO SIGNING THIS AGREEMENT, UNDERSTAND THE TERMS AND CONSEQUENCES OF THIS

AGREEMENT, AND ARE FULLY AWARE OF THE LEGAL AND BINDING EFFECTS OF THIS RESIGNATION AND SEVERANCE

AGREEMENT.

IN WITNESS WHEREOF, the Parties hereto have duly executed this Resignation and Severance
Agreement.

SCM MICROSYSTEMS, INC.:

By:

Name: Stephan Rohaly

Title: Chief Financial Officer and Secretary

Date: June 18, 2007

	 	 	 
	SCM MICROSYSTEMS GMBH:

	 	

	By:

	 	SCM Microsystems, Inc., its sole stockholder
	
 
	 	By:

Name: Stephan Rohaly

Title: Chief Financial Officer and
Secretary

Date: June 18, 2007

EMPLOYEE:

Robert Schneider

Date: June 18, 2007

2

EXHIBIT A

Resignation Letter

	 	 	 
	Ich, der Unterzeichnende, Robert

Schneider, bin Geschäftsführer

der

	 	I, the undersigned Robert

Schneider, am the managing

director of

	 
	Amtsniederlegung/Resignation

	 

SCM Microsystems GmbH

(“Gesellschaft/Company”)

	 	 	 	 	 
	 
	 	with its registered seat in
	mit dem Sitz in Ismaning,
	 	Ismaning, registered with the
	eingetragen im Handelsregister
	 	commercial register of the lower
	des Amtsgerichts München unter
	 	court of Munich under HR B
	HR B 142179.
	 	 	142179.	 

	 	 	 
	Dies vorausgeschickt, lege ich

mein Amt als Geschäftsführer der

Gesellschaft mit Wirkung zum

30.Juni 2007 nieder.

	 	Now, therefore, I resign from my

position as managing director of

the Company with effect from 30

June 2007.

Ismaning, this June 18, 2007

Robert Schneider

3

	 
	Kenntnisnahme/Acknowledgement

	 

	 	 	 
	Von der oben erklärten

Amtsniederlegung habe ich

Kenntnis genommen.

	 	

I acknowledge the resignation

declared above.

SCM Microsystems GmbH

	 	 	 
	vertreten durch ihre

Alleingesellschafterin

	 	

represented by its sole shareholder

SCM Microsystems, Inc.

	 	 	 
	diese vertreten durch

	 	the latter represented by

4

Stephan Rohaly

Managing Director

EXHIBIT B

Equity Benefits

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]